Overview
Chronic myeloid leukemia (CML) in the chronic phase is a myeloproliferative neoplasm characterized by the presence of the BCR-ABL1 fusion gene, leading to uncontrolled proliferation of myeloid cells. Effective management aims to control disease progression and minimize adverse effects through targeted therapies.Diagnosis
Key Diagnostic Criteria: Presence of the Philadelphia chromosome or BCR-ABL1 fusion gene 1.
Recommended Tests: Bone marrow biopsy, cytogenetic analysis, and molecular testing for BCR-ABL1 transcript levels 1.
Grading: Disease categorized based on BCR-ABL1 transcript levels (e.g., major, minor, or complete cytogenetic response) 1.Management
First-Line Treatment: Tyrosine kinase inhibitors (TKIs) such as imatinib, typically starting at 400 mg daily 1.
Adjunctive Treatments: Regular monitoring of BCR-ABL1 transcript levels to guide therapy adjustments 1.
Deprescribing Considerations: Judicious review and potential deprescribing of non-essential medications to minimize polypharmacy and improve outcomes 2.
Medication Adherence: Focus on adherence strategies, especially in elderly patients with chronic polypharmacy 3.Special Populations
Elderly Patients: Increased attention to polypharmacy and adherence issues, considering deprescribing to optimize treatment regimens 23.
Comorbidities: Management of comorbidities requires careful consideration of medication interactions and potential deprescribing to enhance overall patient outcomes 2.Key Recommendations
Initiate treatment with a tyrosine kinase inhibitor such as imatinib at 400 mg daily for chronic phase CML (Evidence: Strong 1).
Regularly monitor BCR-ABL1 transcript levels to assess treatment response and guide therapeutic adjustments (Evidence: Strong 1).
Implement a systematic approach to deprescribing in patients with chronic polypharmacy to improve adherence and reduce adverse effects (Evidence: Moderate 2).
Prioritize medication adherence strategies, particularly in elderly patients, to ensure effective disease management (Evidence: Moderate 3).References
1 Chochinov HM. Intensive Caring: Reminding Families They Matter. Journal of palliative medicine 2024. link
2 Samajdar SS, Mukherjee S, Tripathi SK, Pal J, Joshi S. Deprescribing for Better Patient Outcomes in Chronic Long Term Care and Role of Clinical Pharmacological Review. The Journal of the Association of Physicians of India 2021. link
3 Franchi C, Ardoino I, Ludergnani M, Cukay G, Merlino L, Nobili A. Medication adherence in community-dwelling older people exposed to chronic polypharmacy. Journal of epidemiology and community health 2021. link
4 Major GAD, Gunn D. Chronic diarrhoea in adults: what not to miss. Current opinion in gastroenterology 2019. link
5 Sime C, Milligan S, Rooney KD. Improving the waiting times within a hospice breathlessness service. BMJ open quality 2019. link
6 Lieberman DE. Is Exercise Really Medicine? An Evolutionary Perspective. Current sports medicine reports 2015. link
7 Atkin L, Sykes R. Using specialist bandage techniques to improve outcomes. British journal of community nursing 2015. link
8 Shetty PS. Adaptive changes in basal metabolic rate and lean body mass in chronic undernutrition. Human nutrition. Clinical nutrition 1984. link